Form 4: Natera Executive Sells Shares Under 10b5-1 Plan

Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold 3,000 shares of common stock for approximately $480,000 pursuant to a pre-arranged trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported the sale of 3,000 shares of Natera common stock.
• The transactions occurred on October 1, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• The shares were sold in multiple transactions at weighted average prices ranging from $158.9606 to $160.7008 per share.
• The total value of the shares sold was approximately $480,022.82.
• Following these transactions, Solomon Moshkevich beneficially owns 117,559 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned financial management strategy rather than a reaction to new company developments.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment strategy rather than a reaction to immediate company news.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, though the pre-planned nature of the sale under a 10b5-1 plan mitigates immediate concerns about management's confidence.

Key Dates

Keywords

Natera, NTRA, Solomon Moshkevich, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Clinical Diagnostics, Biotechnology, Healthcare